Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark C Markowski

Showing results (51-60 of 72) with videos related to

Pageof 8
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 31, 2020
Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapyLaura A Sena, Hao Wang, Su J Lim ScM, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 19, 2024
Initial Experience with [<sup>177</sup>Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome PredictionAndrei Gafita, Andrew Voter, Somya Shesadri, et al.
European Urology|July 7, 2020
A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide CohortsMark C Markowski, Hao Wang, Rana Sullivan, et al.
JCO Oncology Practice|February 19, 2026
Comparison of Characteristics and Outcomes of Patients With Metastatic Prostate Cancer With and Without Next-Generation Sequencing TestingMadelyn F Klugman, Hua-Ling Tsai, Yasaman Iranmanesh, et al.
Journal of Neurosurgery. Spine|May 6, 2023
Safety and clinical efficacy of immune checkpoint inhibition and stereotactic body radiotherapy in patients with spine metastasisEmerson Lee, Xuguang Chen, Michael C LeCompte, et al.
Frontiers in Oncology|September 26, 2024
Performance of PSMA-targeted radiotheranostics in an experimental model of renal cell carcinomaRajan Singh, Anand K Thotakura, Suresh Alati, et al.
Annals of Nuclear Medicine|March 1, 2023
Multi-timepoint imaging with PSMA-targeted [<sup>18</sup>F]F-Florastamin PET/CT: lesion detection and comparison to conventional imagingSara Sheikhbahaei, Ricardo Bello Martinez, Mark C Markowski, et al.
The Prostate|May 22, 2023
Test-retest repeatability of organ uptake on PSMA-targeted <sup>18</sup> F-DCFPyL PET/CT in patients with prostate cancerRudolf A Werner, Susanne Lütje, Bilêl Habacha, et al.
JCI Insight|November 16, 2023
MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progressionJiayu Chen, Qizhi Zheng, Jessica L Hicks, et al.
European Urology Oncology|December 12, 2024
Digital Pathology-based Artificial Intelligence Biomarker Validation in Metastatic Prostate CancerMark C Markowski, Yi Ren, Meghan Tierney, et al.
Pageof 8

Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
European Journal of Cancer (Oxford, England : 1990)|December 31, 2020
Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapyLaura A Sena, Hao Wang, Su J Lim ScM, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 19, 2024
Initial Experience with [<sup>177</sup>Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome PredictionAndrei Gafita, Andrew Voter, Somya Shesadri, et al.
European Urology|July 7, 2020
A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide CohortsMark C Markowski, Hao Wang, Rana Sullivan, et al.
JCO Oncology Practice|February 19, 2026
Comparison of Characteristics and Outcomes of Patients With Metastatic Prostate Cancer With and Without Next-Generation Sequencing TestingMadelyn F Klugman, Hua-Ling Tsai, Yasaman Iranmanesh, et al.
Journal of Neurosurgery. Spine|May 6, 2023
Safety and clinical efficacy of immune checkpoint inhibition and stereotactic body radiotherapy in patients with spine metastasisEmerson Lee, Xuguang Chen, Michael C LeCompte, et al.
Frontiers in Oncology|September 26, 2024
Performance of PSMA-targeted radiotheranostics in an experimental model of renal cell carcinomaRajan Singh, Anand K Thotakura, Suresh Alati, et al.
Annals of Nuclear Medicine|March 1, 2023
Multi-timepoint imaging with PSMA-targeted [<sup>18</sup>F]F-Florastamin PET/CT: lesion detection and comparison to conventional imagingSara Sheikhbahaei, Ricardo Bello Martinez, Mark C Markowski, et al.
The Prostate|May 22, 2023
Test-retest repeatability of organ uptake on PSMA-targeted <sup>18</sup> F-DCFPyL PET/CT in patients with prostate cancerRudolf A Werner, Susanne Lütje, Bilêl Habacha, et al.
JCI Insight|November 16, 2023
MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progressionJiayu Chen, Qizhi Zheng, Jessica L Hicks, et al.
European Urology Oncology|December 12, 2024
Digital Pathology-based Artificial Intelligence Biomarker Validation in Metastatic Prostate CancerMark C Markowski, Yi Ren, Meghan Tierney, et al.
Pageof 8